Interestingly, the percentage decrease in serum let-7a levels and the percentage increase in serum IL-6 levels during the early stage of radiotherapy were inversely associated with tumor regression after radiotherapy, suggesting that the treatment plan for esophageal cancer can be adjusted according to alterations in serum let-7a and IL-6 levels during the early stage of radiotherapy. This evidence concerns the gene IL6 and neoplasm.